Kiniksa Pharmaceuticals (KNSA) files Rule 144 notice for option and PSU/RSU shares

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals International, plc submitted a notice covering potential sales of Class A Ordinary Shares under Rule 144. The filing ties shares to an employee stock option exercise dated July 29, 2026 involving 45,049 shares, and to equity compensation (PSU/RSU) from March 16, 2022 involving 22,013 shares, with Charles Schwab & Co., Inc. listed as broker.

Key Figures

Shares linked to option exercise: 45,049 shares Shares linked to PSU/RSU equity compensation: 22,013 shares Other reported figure related to Class A shares: 5,347,344.00 +1 more

4 metrics

Shares linked to option exercise 45,049 shares Employee Stock Option Exercise dated 07/29/2026

Shares linked to PSU/RSU equity compensation 22,013 shares PSU / RSU equity compensation dated 03/16/2022

Other reported figure related to Class A shares 5,347,344.00 Numeric figure presented alongside broker and market details

Additional reported figure related to Class A shares 48,289,273 Numeric figure presented with Class A Ordinary Shares information

Key Terms

Form 144, Employee Stock Option Exercise, PSU / RSU, Broker Payment for Cashless Exercise, +1 more

5 terms

Form 144 regulatory

"144: Securities To Be Sold"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Employee Stock Option Exercise financial

"Class A Ordinary Shares | 07/29/2026 | Employee Stock Option Exercise"

PSU / RSU financial

"Class A Ordinary Shares | 03/16/2022 | PSU / RSU - See Remarks"

Broker Payment for Cashless Exercise financial

"Broker Payment for Cashless Exercise Class A Ordinary Shares"

Equity Compensation financial

"22013 | 03/16/2022 | Equity Compensation"

Equity compensation is pay given to employees, executives or contractors in the form of company ownership—such as stock, stock options or restricted shares—rather than just cash. It matters to investors because it can align workers' incentives with shareholders (like paying someone in slices of the same pie they help grow), but it also increases the number of shares outstanding and company expenses, affecting ownership percentages and earnings per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/29/2026 - 04:04 PM Accepted by SEC EDGAR 07/29/2026 - 04:03 PM Learn about SEC filing dates

FAQ

What does Kiniksa Pharmaceuticals (KNSA) report in this Form 144?

The company reports a planned sale of Class A Ordinary Shares under Rule 144, linked to employee stock option and equity compensation (PSU/RSU) awards, with Charles Schwab & Co., Inc. identified as the executing broker.

How many KNSA shares relate to the employee stock option exercise?

The filing associates 45,049 Class A Ordinary Shares with an Employee Stock Option Exercise dated July 29, 2026. These shares form part of the securities referenced for potential sale under Rule 144 through Charles Schwab & Co., Inc.

What KNSA equity compensation is included in the Form 144?

The notice references 22,013 Class A Ordinary Shares tied to PSU / RSU equity compensation dated March 16, 2022. These award-related shares are listed among the securities that may be sold in reliance on Rule 144.

Which broker is listed for the potential KNSA share sale?

The broker listed is Charles Schwab & Co., Inc., located at 3000 Schwab Way, Westlake, Texas 76262. It appears in connection with the Class A Ordinary Shares referenced in the Rule 144 notice.

Does the KNSA Form 144 confirm that shares have already been sold?

A Form 144 is a notice of proposed sale under Rule 144, not a trade confirmation. It indicates an intent to sell certain Class A Ordinary Shares, but does not itself prove that any sale has occurred.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A Ordinary Shares	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	67062	5347344.00	48289273	07/29/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A Ordinary Shares	07/29/2026	Employee Stock Option Exercise	Kiniksa Pharmaceuticals International, plc			45049	07/29/2026	Broker Payment for Cashless Exercise
Class A Ordinary Shares	03/16/2022	PSU / RSU - See Remarks	Kiniksa Pharmaceuticals International, plc			22013	03/16/2022	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)